Talbot Financial LLC Has $16.10 Million Position in Stryker Co. (NYSE:SYK)

Talbot Financial LLC increased its holdings in Stryker Co. (NYSE:SYK) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 44,722 shares of the medical technology company’s stock after buying an additional 296 shares during the quarter. Stryker comprises approximately 1.9% of Talbot Financial LLC’s portfolio, making the stock its 17th largest holding. Talbot Financial LLC’s holdings in Stryker were worth $16,102,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Parnassus Investments LLC acquired a new position in Stryker in the third quarter worth about $762,798,000. Baltimore Washington Financial Advisors Inc. grew its stake in shares of Stryker by 2.4% during the third quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock valued at $24,089,000 after purchasing an additional 1,554 shares during the last quarter. Sivik Global Healthcare LLC grew its stake in shares of Stryker by 8.0% during the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after purchasing an additional 2,000 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Stryker by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock valued at $210,289,000 after purchasing an additional 16,504 shares during the last quarter. Finally, World Investment Advisors LLC grew its stake in shares of Stryker by 126.1% during the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK traded down $3.19 during midday trading on Monday, hitting $362.47. The stock had a trading volume of 593,769 shares, compared to its average volume of 1,181,281. The company’s 50-day moving average price is $375.40 and its 200-day moving average price is $357.95. The company has a market capitalization of $138.18 billion, a P/E ratio of 38.85, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 EPS. As a group, equities research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.93%. Stryker’s payout ratio is 36.01%.

Insiders Place Their Bets

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SYK shares. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday. Royal Bank of Canada restated an “outperform” rating and set a $425.00 price objective on shares of Stryker in a report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Tuesday, January 7th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.